204758 20230827173150.0 G:(EU-Grant)733203 733203 CORDIS G:(EU-Call)H2020-SC1-2016-RTD H2020-SC1-2016-RTD CORDIS corda__h2020::733203 originalID G:(EU-Grant)733203 Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Segmental Artery Coil-Embolization’: A Randomized Controlled Multicentre Trial 2017-01-01 - 2023-03-31 SLASKIE CENTRUM CHOROB SERCA W ZABRZU SCCS Poland http://www.sccs.pl CORDIS Baylor College of Medicine BCM United States https://www.bcm.edu/ CORDIS University of Bologna UNIBO Italy http://www.unibo.it/en/homepage CORDIS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA CORP PENN United States http://www.upenn.edu CORDIS UNIVERSITAETSKLINIKUM FREIBURG UKLFR Germany http://www.uniklinik-freiburg.de/ip/splash/start.html CORDIS SOCIETE EUROPEENNE DE CARDIOLOGIE ESC/ SEC France http://www.escardio.org CORDIS CHU HOPITAUX DE BORDEAUX CHU Bordeaux France CORDIS University Medical Center Hamburg-Eppendorf UKE Germany http://www.uke.de/ CORDIS OSPEDALE SAN RAFFAELE SRL OSR Italy http://www.hsr.it CORDIS LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LMU MUENCHEN Germany http://www.uni-muenchen.de CORDIS SKANE LANS LANDSTING SKANE LAN Sweden http://www.skane.se CORDIS BARTS AND THE LONDON NHS TRUST BLT United Kingdom http://www.bartsandthelondon.org.uk CORDIS LIVERPOOL HEART AND CHEST HOSPITAL NHS FOUNDATION TRUST LHCH United Kingdom http://www.lhch.nhs.uk CORDIS ASSOCIATION MARIE LANNELONGUE CCML France http://www.hopitalmarielannelongue.fr CORDIS University of Granada UGR Spain http://www.ugr.es/ CORDIS Medical University of Warsaw Medical University of Warsaw Poland http://www.wum.edu.pl/english/ CORDIS Örebro County Council Örebro County Council Sweden http://www.regionorebrolan.se/en/ CORDIS MODUS RESEARCH AND INNOVATION LIMITED United Kingdom http://www.modus.ltd CORDIS Kite Innovation (United Kingdom) Kite Innovation (United Kingdom) United Kingdom CORDIS ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK ECRIN France http://www.ecrin.org CORDIS Leipzig University Leipzig University Germany https://www.uni-leipzig.de/en/ CORDIS Insel Gruppe AG Switzerland http://www.inselgruppe.ch CORDIS ACADEMISCH ZIEKENHUIS MAASTRICHT AZM Netherlands http://www.azm.nl CORDIS University De Lille Université de Lille France https://www.univ-lille.fr CORDIS REGION HOVEDSTADEN REGIONH Denmark http://www.regionh.dk CORDIS H2020-SC1-2016-RTD 2017-01-01 2023-03-31 PAPA-ARTIS d 2017-01-01 - 2023-03-31 I:(DE-588b)5098525-5 European Union CORDIS Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients’ prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in paraplegia from spinal cord ischaemia or even death, particularly for aneurysms extending from the thoracic to the abdominal aorta and thus involving many segmental arteries to the spinal cord, i.e. thoracoabdominal aortic aneurysms of Crawford type II. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10 to 20%. However, it has been found that the deliberate occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord does not increase rates of permanent paraplegia. A therapeutic option, ‘minimally invasive segmental artery coil embolization’ has been devised which proceeds in a ‘staged’ way to occlude groups of arteries under highly controlled conditions after which time must be allowed for arteriogenesis to build a robust collateral blood supply. PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach can reduce paraplegia and mortality dramatically. It can be expected to have both a dramatic impact on the individual patient's quality of life if saved from a wheelchair, and also upon financial systems through savings in; 1) lower costs in EU health care; 2) lower pay-outs in disability insurance (est. at 500k in Year 1), and; 3) loss of economic output from unemployment. Approx. 2500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks. oai:juser.fz-juelich.de:833535 authority:GRANT authority oai:dnet:corda__h2020::0aef41de53911c8b7bc09138dcdb1d81 G CORDIS AUTHORITY oai:juser.fz-juelich.de:833535